IL1A and arthropathy: The rational design of PBAEs has been undertaken to maximise the effectiveness of OA drugs in treating joint diseases considering a multitude of parameters such as not only drug uptake/retention but also chondrocyte viability and post-delivery drug activity in preventing GAG and collage depletion caused by IL-1α.